Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02218879 · ClinicalTrials.gov registry record
Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 7
- Enrollment target
NCT02218879: Clinical Trial study, sponsored by Yale University.
NCT02218879 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02218879 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The primary objective is to directly estimate brain glutathione concentrations in vivo using H-MRS at 7T before and after initiation of Tecfidera in established multiple sclerosis (MS) patients considering switching therapy or being treatment-naive (first line).
Interventions
- DRUG Tecfidera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-04 |
Why NCT02218879 stopped before completion
NCT02218879 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Tecfidera is the first listed.
NCT02218879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02218879 about?
NCT02218879 is a clinical study titled "Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS". The primary objective is to directly estimate brain glutathione concentrations in vivo using H-MRS at 7T before and after initiation of Tecfidera in established multiple sclerosis (MS) patients considering switching therapy or being treatment-naive (first line).
What is the current status of trial NCT02218879?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2014-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02218879?
The interventions under investigation include: Tecfidera (DRUG).
Who is sponsoring clinical trial NCT02218879?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia